Matinas BioPharma receives FDA feedback on Phase 3 protocol for MAT2203; meeting set for early Q1 2024

Matinas BioPharma Holdings, Inc.

FDA provided written comments on revised Phase 3 protocol for MAT2203 in invasive aspergillosis with limited treatment options.
Company invited to meeting early Q1 2024 to finalize Phase 3 study design.
Partnership discussions for MAT2203 remain ongoing.
Goal is single Phase 3 registration trial for approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.